The deal added CAR-T candidate to Gilead's existing portfolio. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. A high-level overview of Kite Pharma (KITE) stock. Gilead and its shiny new $12 billion biotech buy Kite Pharma have teamed up with Big Pharma Pfizer to work on a Yescarta-utomilumab combination ... through its $12 billion buyout of Kite … The acquisition was completed in October 2017. Kite ex­ecs had a chance to talk about re­tain­ing Kite staff. Gilead's buyout of cell therapy specialist Kite Pharma has drawn considerable criticism from skeptical Wall Street analysts in the two and a half years since the $12 billion deal was signed. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. The deal marked another major immuno-oncology move on Gilead’s part since its $11.9 billion acquisition of Kite Pharma in 2017, which gave it CAR-T drug Yescarta. On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, equating to $180 cash per share. In October 2017, Kite Pharma’s (previously publicly traded as “KITE”) therapy, Yescarta became the first CAR-T therapy approved by the FDA for the treatment of adult patients with certain types of lymphoma after two or more lines of systemic therapy. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Sul­li­van & Cromwell weighed in. And on Au­gust 28, the deal was done at $180 a share, or close to $12 bil­lion in to­tal. After Pfizer outbid Gilead for Medivation last September, Todd Hagopian named 4 companies Gilead might go after next. Back to … But following Gilead's decision to acquire Kite Pharma in … The big news for the week in the biotech space is the huge $12 billion buyout of Kite Pharma Inc (NASDAQ: KITE) by Gilead Sciences, Inc. (NASDAQ: GILD).. Gilead, Kite … On Monday, Gilead Sciences announced a blockbuster acquisition of Kite Pharma , and all of a sudden, summer ended before Labor Day. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. Kite Pharma, then trading at about $55, was among them. Gilead (GILD) And Its Acquisition of Kite Pharma – Buyout Valued At $11.9 Billion. Gilead Sciences to Acquire Kite Pharma for $11.9 Billion -- Immediately Positions Gilead as a Leader in Cell Therapy---- Kite's Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU ---- Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation -- August 28, 2017. Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. Gilead Sciences agreed to buy Kite Pharma in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to …